Showing 1 - 20 results of 23 for search 'P Rodriguez-Otero', query time: 0.05s
Refine Results
-
1
P973: REAL-WORLD STUDY ON ADOPTION OF STANDARD OF CARE (SOC) FOR FRONTLINE TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (FLTEMM) PATIENTS BETWEEN 2017 AND 2020/2021 ACROSS FRANCE, GERMANY,... by K. Weisel, A. Wadlund, G. Gungor, E. Dergarabetian, C. Pacheco, N. Masurkar, P. Rodriguez-Otero
Published 2022-06-01
Article -
2
P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY by P Rodríguez-Otero, J San-Miguel, LD Anderson, Jr, S Lonial, A Truppel-Hartmann, J Sanford, E Rowe, TB Campbell, N Munshi
Published 2022-04-01
Article -
3
P19: BASELINE CORRELATES OF COMPLETE RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYEL... by P Rodríguez-Otero, N Shah, N Munshi, J Berdeja, S Jagannath, O Finney, N Martin, A Agarwal, E Rowe, T Campbell, J San-Miguel
Published 2022-04-01
Article -
4
TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D (GPRC5D) CD3 BISPECIFIC ANTIBODY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 STUDY RESULTS by JG Berdeja, AY Krishnan, A Oriol, NWV Donk, P Rodríguez-Otero, E Askari, M Mateos, MC Minnema, LJ Costa, R Verona, BW Hilderq, S Girgisq, T Prior, JS Russell, JD Goldberg, A Chari
Published 2021-10-01
Article -
5
P1463: PHASE I DOSE ESCALATION OF LAVA-051, A NOVEL BISPECIFIC GAMMA-DELTA T-CELL ENGAGER (GAMMABODY™), IN RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES by A. Broijl, N. van de Donk, F. Bosch, M. V. Mateos, P. Rodriguez-Otero, A. Tucci, P. Ghia, A. Adang, P. Parren, I. Tuinhof, S. Umarale, B. Winograd, H. van der Vliet, A. Kater
Published 2022-06-01
Article -
6
S182: TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED EFFICACY AND SAFETY RESULTS FR... by M. C. Minnema, A. Krishnan, J. G. Berdeja, A. Oriol, N. W. van de Donk, P. Rodríguez-Otero, D. Morillo, M.-V. Mateos, L. J. Costa, J. Caers, D. Vishwamitra, J. Ma, S. Yang, B. W. Hilder, J. Tolbert, J. D. Goldberg, A. Chari
Published 2022-06-01
Article -
7
P10: TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 RE... by N. W. C. J van de Donk, M C Minnema, J G Berdeja, A Oriol, A Krishnan, P Rodríguez-Otero, E Askari, M Mateos, L. J Costa, R Verona, J Ma, S Girgis, S Yang, B. W Hilder, J Russell, J. D Goldberg, A Chari
Published 2022-04-01
Article -
8
P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING-ADJUSTED INDIRECT TREATMENT COMP... by M. Delforge, S. Z. Usmani, N. W. van de Donk, A. L. Garfall, P. Moreau, A. Oriol, A. K. Nooka, L. Rosinol, N. Bahlis, P. Rodriguez-Otero, T. Martin, J. Diels, S. Van Sanden, L. Pei, E. Ammann, R. Kobos, M. Slavcev, J. Smit, A. Londhe, A. Krishnan
Published 2022-06-01
Article -
9
S188: TECLISTAMAB IN COMBINATION WITH DARATUMUMAB, A NOVEL, IMMUNOTHERAPY-BASED APPROACH FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS by P. Rodriguez Otero, A. D’Souza, D. Reece, N. W. van de Donk, A. Chari, A. Krishnan, T. Martin, M. V. Mateos, D. Morillo, D. Hurd, L. Rosinol, A. S. Balari, R. Wäsch, D. Vishwamitra, S. X. Wang Lin, T. Prior, L. Vandenberk, M.-A. D. Smit, A. Oriol, B. Dholaria
Published 2022-06-01
Article -
10
PB2014: TECLISTAMAB VS SELINEXOR-DEXAMETHASONE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING-ADJUSTED INDIRECT COMPARISON by L. Rosinol, S. Z. Usmani, N. Bahlis, A. Y. Krishnan, A. K. Nooka, A. Oriol, M. Delforge, A. L. Garfall, N. W. van de Donk, P. Rodríguez Otero, T. G. Martin, J. Diels, S. Van Sanden, L. Pei, E. Ammann, R. Kobos, M. Slavcev, J. Smit, A. Londhe, P. Moreau
Published 2022-06-01
Article -
11
B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL... by P. Rodríguez-Otero, S. Ailawadhi, B. Arnulf, K. Patel, M. Cavo, A.K. Nooka, S. Manier, N. Callander, L.J. Costa, R. Vij, N.J. Bahlis, P. Moreau, S.R. Solomon, M. Delforge, J. Berdeja, A. Truppel-Hartmann, Z. Yang, L. Favre-Kontula, F. Wu, J. Piasecki, M. Cook, S. Giralt
Published 2023-05-01
Article -
12
P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN? by R Popat, A Badros, S Kumar, P Rodriguez-Otero, A Cohen, S Manier, P Voorhees, F Gay, R Rifkin, T Martin, A Chari, K Weisel, A Farooq, B Jeng, W Chng, H Lee, J Berdeja, V Jadhav, A Tosolini, L Eliason, A Palumbo, M Dimopoulos, S Lonial, S Trudel, P Richardson, E Terpos
Published 2022-04-01
Article -
13
B04: COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY by P Rodriguez-Otero, B Dholaria, E Askari, D Reece, N van de Donk, A Chari, H Goldschmidt, A Krishnan, T Martin, M Mateos, D Morillo, C Rodriguez, L Rosinol, J San-Miguel, A Balari, R Wäsch, K Weisel, R Verona, S Lin, T Prior, M Wade, B Weiss, J Goldberg, A Oriol, P Hari
Published 2022-04-01
Article -
14
B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS by M Mateos, P Hari, N Bahlis, A Chari, NWCJ van de Donk, B Dholaria, AL Garfall, H Goldschmidt, KM Kortüm, A Krishnan, T Martin, D Morillo, A Oriol, D Reece, C Rodriguez, P Rodríguez-Otero, JF San-Miguel, SZ Usmani, R Verona, SXW Lin, TJ Prior, M Wade, B Weiss, JD Goldberg, E Askari
Published 2022-04-01
Article -
15
P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON-CELLULAR ANTI-B-CELL MATURATION ANTIGEN (B... by N. van de Donk, M.-V. Mateos, Y.C. Cohen, P. Rodriguez-Otero, B. Paiva, A.D. Cohen, T. Martin, A. Suvannasankha, D. Madduri, C. Corsale, J.M. Schecter, K.C. De Braganca, C.C. Jackson, H. Varsos, W. Deraedt, T. Roccia, P. Mistry, X. Xu, K. Li, E. Zudaire, M. Akram, L. Pacaud, I. Avivi, J. San-Miguel
Published 2023-05-01
Article -
16
P42 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISP... by N. van de Donk, L. Rasche, C. Touzeau, A. Chari, C. Schinke, M. Minnema, J. Berdeja, A. Oriol, P. Rodriguez-Otero, E. Askari, M. Mateos, L. Costa, J. Caers, A. Krishnan, D. Vishwamitra, J. Ma, X. Qin, K.S. Gries, K. Kato, M. Campagna, T. Masterson, B. Hilder, J. Tolbert, T. Renaud, J. Goldberg, C. Heuck, P. Moreau, J. San-Miguel
Published 2023-05-01
Article -
17
Dreamm-2: single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma (rrmm), including subgroups with renal impairment (ri) and high-risk (hr) cytogen... by S. Lonial, H.C. Lee, A. Badros, S. Trudel, A.K. Nooka, A. Chari, A-O. Abdallah, N.S. Callander, D.W. Sborov, A. Suvannasankha, K. Weisel, P.M. Voorhees, M. Hultcrantz, E.N. Libby, P.G. Richardson, P. Rodriguez Otero, B. Besemer, T. Facon, A. Hoos, J. Baron, T. Piontek, R.C. Jewell, E. Lewis, J. Opalinska, I. Gupta, A.D. Cohen, A. Medaglia
Published 2020-09-01
Article -
18
S183: NOVEL COMBINATION IMMUNOTHERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS FOR TALQUETAMAB (A GPRC5D X CD3 BISPECIFIC ANTIBODY) IN CO... by N. W. van de Donk, N. Bahlis, M.-V. Mateos, K. Weisel, B. Dholaria, A. L. Garfall, H. Goldschmidt, T. G. Martin, D. Morillo, D. E. Reece, D. Hurd, P. Rodríguez-Otero, M. Bhutani, A. D’Souza, A. Oriol, E. Askari, J. F. San-Miguel, K. M. Kortüm, D. Vishwamitra, S. Xin Wang Lin, T. J. Prior, L. Vandenberk, M.-A. D. Smit, J. D. Goldberg, R. Wäsch, A. Chari
Published 2022-06-01
Article -
19
P1593: IMMUNE BIOMARKERS TO PREDICT SARS-COV-2 VACCINE EFFECTIVENESS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES by L.-E. Tamariz-Amador, A. M. Battaglia, C. Maia, A. Zherniakova, C. Guerrero, A. Zabaleta, L. Burgos, C. Botta, M.-A. Fortuño, D. Alignani, L. Blanco, C. Grande, A. Manubens, J.-M. Arguiñano, C. Gomez, E. Perez-Persona, I. Olazabal, I. Oiartzabal, C. Panizo, F. Prosper, J. F. San Miguel, P. Rodriguez-Otero, E. Martín-Sánchez, B. Paiva, A. V.-N. H.-H. ASOVASNA
Published 2022-06-01
Article -
20
P862: SERUM MASS SPECTROMETRY TO ANALYZE DISEASE RESPONSE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING ARI0002H, AN ACADEMIC BCMA-DIRECTED CAR T-CELL THERAPY by I. Ortiz De Landazuri, A. Oliver-Caldés, M. Español-Rego, M. T. Contreras, A. Zabaleta, C. Agulló, N. Puig, V. Cabañas, V. González-Calle, R. Jiménez, S. Inogés, P. Rodríguez-Otero, B. Martin-Antonio, J. L. Reguera, A. López-Diaz de Cerio, D. Benítez-Ribas, L. G. Rodríguez-Lobato, E. A. González, L. Rosiñol, J. Yagüe, J. M. Moraleda, Á. Urbano-Ispizua, M. V. Mateos, M. Juan, B. Paiva, M. Pascal, C. Fernández de Larrea
Published 2022-06-01
Article